GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » EV-to-FCF

Resverlogix (TSX:RVX) EV-to-FCF : -4.41 (As of May. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Resverlogix's Enterprise Value is C$24.30 Mil. Resverlogix's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was C$-5.51 Mil. Therefore, Resverlogix's EV-to-FCF for today is -4.41.

The historical rank and industry rank for Resverlogix's EV-to-FCF or its related term are showing as below:

TSX:RVX' s EV-to-FCF Range Over the Past 10 Years
Min: -14.44   Med: 0   Max: 58.39
Current: -4.43

During the past 13 years, the highest EV-to-FCF of Resverlogix was 58.39. The lowest was -14.44. And the median was 0.00.

TSX:RVX's EV-to-FCF is ranked worse than
100% of 369 companies
in the Biotechnology industry
Industry Median: 8.9 vs TSX:RVX: -4.43

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-29), Resverlogix's stock price is C$0.055. Resverlogix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.049. Therefore, Resverlogix's PE Ratio for today is At Loss.


Resverlogix EV-to-FCF Historical Data

The historical data trend for Resverlogix's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix EV-to-FCF Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.28 -7.75 -11.68 -8.29 -6.85

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.44 -15.37 75.25 -6.85 -4.40

Competitive Comparison of Resverlogix's EV-to-FCF

For the Biotechnology subindustry, Resverlogix's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Resverlogix's EV-to-FCF falls into.



Resverlogix EV-to-FCF Calculation

Resverlogix's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=24.299/-5.505
=-4.41

Resverlogix's current Enterprise Value is C$24.30 Mil.
Resverlogix's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-5.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Resverlogix  (TSX:RVX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Resverlogix's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.055/-0.049
=At Loss

Resverlogix's share price for today is C$0.055.
Resverlogix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.049.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Resverlogix EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Resverlogix's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix (TSX:RVX) Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines